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Abstract
Background: Nitric oxide (NO) plays an important role in mobilization of endothelial progenitor cells (EPCs). We
hypothesized that inhaled NO (iNO) would induce EPC mobilization and therefore promote lung repair in acute respiratory
distress syndrome (ARDS).
Methodology/Principal Findings: Healthy piglets were randomized into four groups (n=6): Control (Con; mechanical
ventilation only); ARDS (established by oleic acid infusion and mechanical ventilation); ARDS plus granulocyte-colony
stimulating factor (G-CSF; 10 mg/kg/d subcutaneously); ARDS plus NO inhalation (iNO; 10 ppm). EPCs and mobilizing
cytokines were assayed at different time points (baseline, 0, 24, 72 and 168 h) and injury reparation was assessed at 168 h.
Compared to the Con group, the levels of EPCs were increased in bone marrow but not in blood in the ARDS group at 24 h.
Compared to the ARDS group, inhaled NO induced a rapid elevation in the number of CD34
+KDR
+, KDR
+CD133
+ and
CD34
+KDR
+CD133
+ EPCs in blood (21636454 vs. 10946416, 13026413 vs. 4296244, 11406494 vs. 4536273 cells/ml,
respectively, P,0.05), and a reduction in the percentage of KDR
+CD133
+ cells in bone marrow. Lung CD34, CD133, VEGF,
VEGF receptor 2, endothelial NO synthase mRNA, and VEGF and VEGF receptor 2 protein expression levels were augmented
in the iNO group, but not in the G-CSF group, compared to ARDS. Furthermore, iNO treatment reduced vascular
permeability, increased pulmonary vessel density, and alleviated pulmonary edema and inflammation compared to ARDS
treatment. Plasma VEGF, stromal cell-derived factor-1 (SDF-1) and bone marrow NO2
2/NO3
2 were significantly higher in the
iNO group compared to the ARDS group at 72 h.
Conclusions: These results suggest that iNO induces mobilization of EPCs from bone marrow into circulation, contributes to
vascular repair, and thereby alleviates lung damage.
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Introduction
Acute lung injury (ALI) and acute respiratory distress syndrome
(ARDS) remain important challenges for pediatric intensive care
units [1]. Mortality from ARDS approximates 40% despite the
advances in supportive and pharmacologic treatment [2–4].
Diffuse endothelial damage plays a critical role in the pathogenesis
of ALI/ARDS. Data from animal models of ALI demonstrate that
up to 50% of lung capillaries are lost and large and small vessels
within the lung are damaged during ALI/ARDS [5]. Regenera-
tion of pulmonary endothelium has been suggested as one of the
potential therapeutic targets for ARDS [6].
Accumulating evidence suggests that EPCs are mobilized from
bone marrow and recruited into tissue to contribute to lung repair
after injury. The number of EPCs has been shown to be acutely
elevated in circulation, and this increase was associated with the
repair of damaged pulmonary endothelium in mice with lung
injury [7]. Moreover, patients with low EPC counts reportedly
have persistent fibrotic changes in lung tissue after recovery from
pneumonia [8], the numbers of EPCs were increased in ALI
patients and an adverse outcome was associated with a lower EPC
number [9]. Our previous study showed that the level of EPCs was
increased in blood and unaltered in bone marrow in animals with
moderate lung injury (200 mmHg#PaO2/FiO2#300 mmHg). In
contrast, the level of EPCs was unaltered in blood but elevated in
bone marrow in animals with severe lung injury (PaO2/
FiO2#200 mmHg; unpublished observations). These studies
suggest that increased circulating EPCs contribute to lung repair
in ALI, however the mobilization of EPCs from bone marrow is
inhibited in severe lung injury, and thus a lack of sufficient EPCs in
circulation might result in an impaired repair process. Therefore,
we hypothesize that mobilization of EPCs might provide an
effective strategy for restoring pulmonary endothelial function and
reducing severity of ARDS.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33859Several cytokines have been used to mobilize EPCs from bone
marrow in cardiovascular diseases [10]. However, currently the
use of mobilizing cytokines in ALI is hampered by the fact that
most powerful mobilizers, such as granulocyte colony-stimulating
factor (G-CSF), also exert a pro-inflammatory effect and may have
the potential to promote tumor growth [11]. There is a critical
need to search for more safe and effective mobilizers for EPC
therapy in ARDS.
Recent studies have demonstrated that endothelial nitric oxide
synthase (eNOS) and nitric oxide (NO) play an important role in
EPC mobilization [12–14]. eNOS transcription enhancer and NO
donor supplementation could increase EPC number and improve
EPC function in ischemic diseases [15–18]. Inhaled NO (iNO) was
first used as a vasodilator to selectively dilate pulmonary vessels,
and was then shown to have anti-inflammatory effects on the lung
[19]. More recent studies have shown that iNO therapy could
improve pulmonary angiogenesis. Experimental studies showed
that iNO preserved vascular growth and enhanced alveolarisation
in newborn rat models of vascular endothelial growth factor
receptor (VEGFR2) inhibition, eNOS-deficient and hyperoxia
[20–22]. Recently, it has been reported that iNO restored vessel
density and improved lung structure in neonatal rat model of
bronchopulmonary dysplasia (BPD) [23]. Our previous animal
studies also indicated that inhaled NO can attenuate the lung
Table 1. General conditions and oxygenation values at 0 h.
Group (n=6) Weight (kg) Sex (M/F) PaO2/FiO2 (mmHg) Cdyn (ml/cmH2O/kg)
Con 7.860.8 3/3 357639.0 1.260.3
ARDS 8.361.4 3/3 133615.0 0.560.2
G-CSF 8.360.7 4/2 140622.1 0.660.1
iNO 8.860.9 2/4 135625.3 0.660.1
Values are means 6 SD. Cdyn, dynamic compliance.
doi:10.1371/journal.pone.0033859.t001
Figure 1. Representative cytograms for the determination of CD34
+, CD133
+, CD34
+KDR
+, KDR
+CD133
+ and CD34
+KDR
+CD133
+
cells from animals. (A) A gate P1 enclosing the mononuclear cells for further selection. P1 selected mononuclear cells are examined for the
expression of CD34
+ cells (B) or CD133
+ cells(C). (D) CD34
+ events from P2 are examined further for the expression of VEGFR2 (KDR). (E) CD133
+ events
from P3 are examined for the expression of KDR. (F) CD34
+ events from P2 are examined for expression of KDR and CD133. The upper right represents
events that are CD34
+KDR
+CD133
+.
doi:10.1371/journal.pone.0033859.g001
iNO Enhances EPC Mobilization Improves Lung Repair
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33859injury score in hyperoxic lung injury and ALI animals [24,25].
However, it is unknown whether iNO can mobilize bone marrow
EPCs and consequently promote lung vascular repair.
The aim of this study was to observe the dynamic changes of
circulating EPCs, and to further investigate the effect of iNO on EPC
mobilization and lung vascular reparation in both acute and recovery
phases, using an oleic acid induced ARDS model in young piglets.
Methods
Ethics statement
Animal study protocols were approved by the Scientific and
Ethics Committees at Children’s Hospital of Fudan University
(Approval Number: 2007001), and were in compliance with the
Chinese national regulations on the use of experimental animals.
Study animals and protocols
Twenty-four healthy piglets were used in this study. Each animal
was anesthetized intramuscularly with 50 mg/kg ketamine and
orally intubated with a cuffed endotracheal tube. Mechanical
ventilation was initiated in pressure-control ventilation (PCV) mode
(Servo 300, Siemens-Elema, Sweden), with a frequency of 15
breaths/min, a positive end-expiratory pressure (PEEP) of
2 cmH2O, an inspiration time of 0.33 s, and an inspired oxygen
fraction (FiO2) of 0.21. The PEEP was adjusted to 6 cmH2O after
the induction of ARDS, and the ventilator settings were adjusted to
provide a tidal volume of 6–8 ml/kg and to maintain target PaO2
(.60 mmHg) and PaCO2 (30–50 mmHg). The anesthesia was
maintained by continuous infusion of ketamine (10 mg/kg/h) and
fentanyl (5 mg/kg/h). A central venous catheter was placed into the
right external jugular vein for drug administration. A thermodilu-
tion catheter (4 Fr, PiCCO plus system, Pulsion Medical Systems)
was placed into the right internal carotid artery and connected to a
PiCCOplus monitor (Pulsion Medical Systems). The baseline (B)
was defined upon stabilization of animals after the operation.
The animals were randomly assigned into each of the following
4 groups (n=6 each): Con group, where normal animals were
ventilated; ARDS group, which was established and treated with
mechanical ventilation; G-CSF group, where a subcutaneous
injection of G-CSF (a commonly used agent for EPCs mobilizing)
was administered to ARDS animals at a dose of 10 mg/kg daily for
7 days; and iNO group, where inhaled NO (10 ppm) was
administered to ARDS animals during ventilation and NO gas
at 1000 ppm (Noventek) was supplied to the inspiratory line of the
ventilator circuit [25–27].
ARDS was established by a slow, 30-min intravenous infusion of
0.13–0.15 ml/kg oleic acid (01008; Sigma) suspended in 15 ml of
saline via a central venous catheter. ARDS was defined as PaO2/
FiO2#200 mmHg, with dynamic lung compliance (Cdyn) de-
creased by more than 50% from its baseline level, and histological
evidence of bilateral infiltration of inflammatory cells in the lung
(verified by our pilot study in 2 additional piglets) according to
previous reports [25,26]. The moment lung injury was established
was defined as treatment time 0 h. There were no differences in
the body weight among the four groups, and no difference in
PaO2/FiO2 and Cdyn was found among ARDS, iNO and G-CSF
group at time 0 (Table 1, Table S1). Animals were ventilated for
48–72 h and then weaned and fed for recovery until day 7. At
different time points (B, 0, 24, 72 and 168 h), blood or bone
marrow samples were collected for further analysis.
Lung hemodynamics
Extravascular lung water (EVLW), EVLW index (ELWI) and
pulmonary vascular permeability index (PVPI) were determined
using the PiCCOplus monitor to evaluate the pulmonary vascular
permeability and pulmonary edema at B, 0, 2, 6, 12 and 24 h.
Flow cytometric analysis
Blood was collected from the arterial catheter in each animal.
Bone marrow was obtained by aspiration of the posterior iliac
crest. The EPC levels were assessed by flow cytometry using cell
surface antigens in different combinations (CD34
+KDR
+,
KDR
+CD133
+,a n dC D 3 4
+KDR
+CD133
+ cells) as previously
reported [8,28,29]. Briefly, before staining with specific mono-
clonal antibodies, cells were treated with fetal calf serum for
10 minutes, and then the samples were washed with PBS. Then,
100 ml of peripheral blood or bone marrow sample was
incubated with 10 ml FITC-conjugated CD34 monoclonal
antibodies (mAbs) (348053, BD Biosciences, San Jose, CA,
USA), 5 ml of APC-conjugated CD133 mAb (130-090-826,
Miltenyi Biotec, Bergisch Gladbach, Germany), and 10 mlo fP E -
conjugated KDR mAb (FAB357P, R&D Systems, Minneapolis,
MN), followed by incubation at 4uC for 30 min. Red cells were
lysed and the frequency of EPCs was determined by a two-
dimensional forward scatter/fluorescence dot plot analysis of the
samples (FACSAria; BD Biosciences, Franklin Lakes, NJ).
Isotype controls were used for setting gates and determining
the positive/negative boundaries, and the analysis was confirmed
by running the FMO (fluorescence-minus-one) controls. After
morphological gating to exclude granulocyte and cell debris, we
gated CD34
+ or CD133
+ cells and then examined the resulting
population for dual expression of KDR, and triple positive cells
were identified by the dual expression of KDR and CD133 in
the CD34 gate (Figure 1A–F). About 500,000 cells were
acquired. The levels of EPC were expressed as number of cells
per milliliter of blood, and as percentage of total mononuclear
cells (MNC) in bone marrow. We did not test the absolute
number of EPCs in bone marrow due to the inability to obtain
the bone marrow cell counts by the hematology analyzer. The
same trained operator, who was blind to the experiment,
performed all the tests throughout the study.
ELISA
The plasma concentrations of VEGF and stromal cell-derived
factor-1 (SDF-1) were quantified by commercial ELISA kits. The
ELISA was performed according to the manufacturer’s instructions.
Lung processing
At the end of the experiment, the animals were sacrificed with
intravenous injection of 10% potassium chloride. After the thorax was
opened, lungs and heart were removed en bloc. Lung tissue from the
tip of the right mid-lobe was used for wet-to-dry weight (W/D) ratio
analysis. The rest of the mid-lobe was immediately frozen in liquid
Table 2. Primers used in quantitative PCR.
Gene Forward-sense primer Reverse-antisense primer
VEGFR2 59CGGAAATGACACTGGAGC39 59TTCTGGATACCTCGCACA39
CD34 59ACTGCCTGCTGCTGGTCT39 59GCTCTGGTGGCTCCTAACAT39
CD133 59TCTTTTGTTCCTGCCGTTG39 59ACCATAGATGATACCGATGCTTA39
VEGF 59CCTTGCTGCTCTACCTCC39 59CTCCAGTCCTTCGTCGTT39
eNOS 59GTGGTAACCAGCACCTTTGG39 59GCAGGAAACACTATTGAAGC39
GAPDH 59GGTCGGAGTGAACGGATTTG39 59TTCTCAGCCTTGACTGTGCC39
doi:10.1371/journal.pone.0033859.t002
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olar lavage of the right lung was performed with sterile saline via an
intracheal tube [30]. The left lung was fixed by perfusion for 30 min
via the pulmonary artery with 4% paraformaldehyde in PBS. Lung
permeability index (LPI) was measured by determining the ratio of
bronchoalveolar lavage fluid protein to plasma protein.
Morphometric analysis
Sections stained with hematoxylin and eosin were examined by
light microscopy for injury patterns and severity as assessed by
lung injury scores for edema, neutrophil infiltration, hemorrhage
and bronchiole epithelial desquamation [25,26,30].
Immunohistochemistry and vessel density
Fixed lungs were paraffin-embedded and sections were prepared
by subsequent deparaffinization and rehydration [27]. The sections
were incubated with rabbit polyclonal antibodies against factor VIII
(CP039A, 1:200, Biocare Medical, Walnut Creek, USA), VEGFR2
(KDR) (ab45010, 1:100; Abcam, Cambridge, UK) and eNOS
(ab5589, 1:100; Abcam, Cambridge, UK) at room temperature for
2 h and then overnight at 4uC. Sections were then incubated with
corresponding biotinylated secondary antibodies for 45 min at
37uC followed by avidin-biotin-peroxidase for 45 min at 37uC
(Vectastain Elite ABC kit; 1:200, Vector Laboratories). The sections
were then developed with diaminobenzidine (DAB) and H2O2 and
lightly counterstained with hematoxylin. To analyze the vessel
density,5fieldsineachslicewererandomlyselected.Thenumberof
vessels was counted using a light microscope at 2006magnification.
Results were expressed as number of vessels per field.
Apoptosis
Lung tissue was analyzed for terminal deoxynucleotidyl
transferase dUTP-mediated nick-end labeling (TUNEL) using
the DeadEnd Colorimetric TUNEL System (Promega, Madison,
WI) according to the manufacturer’ protocol. As a negative
control, the TdT enzyme was omitted in parallel reactions. All
sections were counterstained with hematoxylin after TUNEL
staining. The ratio of TUNEL-positive cells to total cells (apoptotic
index) was calculated from three random, non-overlapping fields
at 4006magnification for each section.
Quantitative real-time PCR
Total lung RNA was extracted from frozen lung tissue using
Trizol Reagent and was reverse-transcribed into cDNA. The
primer sequences of target genes VEGF, VEGFR2, eNOS, CD34
and CD133 are described in Table 2. GAPDH was used as a
loading control. Real-time PCR was conducted for quantitative
analysis using SYBR Green PCR Master Mix as per manufactur-
er’s instructions (TOYOBO, Japan). The endpoint used in the
real-time PCR quantification was defined as the PCR cycle
number that crossed the signal threshold (Ct). After validation of
amplification efficiencies of two genes, quantification of target
gene expression was calculated by the comparative Ct method.
Western blot analysis
Lung tissue samples were analyzed for VEGF and VEGFR2
protein expression with western blot analysis. Briefly, forty micro-
grams of total protein were separated by SDS-PAGE and then
transferred to a nitrocellulose membrane by electroblotting. Blots
were blocked for 2 h in 10% nonfat dry milk in TBST with 0.1%
Tween 20 at room temperature. Immunodetection was performed
Table 4. EPC number in peripheral blood from animals of different groups.
Group Baseline (n=6) 0 h (n=6) 24 h (n=6) 72 h (n=5–6) 168 h (n=5–6)
CD34
+KDR
+ cells(cells/ml) Con 11646799 9556536 12386643 11666685 10326634
ARDS 11456703 9756637 10946416 11766603 10246330
G-CSF 11606440 9666539 143061011 409761468* 571563505*
iNO 11516277 9556375 21636454* 21986671* 21006794*{
CD34
+KDR
+CD133
+ cells (cells/ml) Con 4246314 4786381 4976268 4006216 4556287
ARDS 4046275 4236278 4536273 3666191 3136198
G-CSF 4166225 3776127 4516230 7976323 9016506*
iNO 4356125 382674 11406494*{ 8226321 7396303
KDR
+CD133
+ cells(cells/ml) Con 4866364 5096375 5446303 4986276 5076227
ARDS 4596300 3566202 4296244 4686249 4066281
G-CSF 4466264 3606182 5536375 8676488 14206572*
iNO 5146175 4426113 13026413*{ 10566347* 9526272*
Values are means 6 SD.
*P,0.05 vs. ARDS;
{P,0.05 vs. G-CSF.
doi:10.1371/journal.pone.0033859.t004
Table 3. Total numbers of WBCs (610
9/L) in different groups
at different time points.
Group
Baseline
(n=6)
0h
(n=6)
24 h
(n=6)
72 h
(n=5–6)
168 h
(n=5–6)
Con 19.163.5 18.463.3 19.264.1* 18.363.3 17.161.7*
ARDS 20.966.4 17.663.1 12.261.8{ 15.961.5{ 13.761.4{
G-CSF 18.163.6 16.862.8 30.569.1**{ 38.3621.5**{ 42.6629.8**{
iNO 21.365.9 18.664.4 19.568.1* 19.965.6 16.863.6
Values are means 6 SD.
*P,0.05 vs. ARDS;
**P,0.01 vs. ARDS;
{P,0.05 vs. Baseline.
doi:10.1371/journal.pone.0033859.t003
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sis Biotechnology) and rabbit polyclonal VEGFR2 antibody
(ab45010, 1:250, Abcam, Cambridge, UK) at room temperature
for 1 h and overnight at 4uC. After the blots were washed to remove
unbound antibody, a horseradish peroxidase-conjugated secondary
antibody (Jackson Immunoresearch, West Grove, PA) was applied for
1 h at room temperature. After washing, bands were visualized with
SuperSignal West Pico chemiluminescent substrate (Thermo Fisher
Scientific, Rockford, IL). b-actin (bs-0061R, 1:500, Biosynthesis
Biotechnology) was used as a loading control. Image J software was
used to perform densitometry measurements.
NO assay
NO production in bone marrow plasma was evaluated by
measuring the total NO2
2/NO3
2 by Griess reaction (Nanjing
Jiancheng Bioengineering Institute).
Gelatin zymography
Gelatin zymography was performed as described elsewhere
[31]. Bone marrow samples were diluted in non-reducing sample
buffer and 4 ı `l of sample was added to each lane. The samples were
electrophoresed in 10% polyacrylamide gels containing 2 mg/ml
gelatin. After electrophoresis, gels were washed in 2.5% Triton X-
100 for 1 h, incubated for 18 h at 37uC in development buffer, and
stained for 3 h with 0.1% Coomassie Brilliant Blue. Gelatinolytic
activity of matrix metallopeptidase 9 (MMP-9) was detected as
transparent bands on the Coomassie Brilliant Blue-stained gels.
Statistical analysis
All the continuous data are presented as means and SD.
Continuous parametric variables were subjected to ANOVA,
followed by post-hoc test of Bonferroni for between-group
differences, and by paired samples t test for within-group
differences. Nonparametric variables were subjected to Kruskal-
Wallis test for differences among groups, followed by Wilcoxon-
Mann-Whitney test for between-group differences. A P val-
ue,0.05 was regarded as statistically significant.
Results
Inhaled NO induces rapid mobilization of bone marrow
EPCs into circulation
In the G-CSF group, the WBC counts gradually increased
compared to the ARDS group (Table 3). Moreover, the total
Table 5. EPC level in bone marrow from animals of different groups.
Group Baseline (n=6) 24 h (n=6) 72 h (n=5–6)
CD34
+KDR
+ cells/MNC, % Con 0.01460.005 0.01760.005 0.01460.004
ARDS 0.01460.009 0.05060.020{ 0.01860.005
G-CSF 0.01360.009 0.02160.014 0.01760.013
iNO 0.01260.006 0.02660.014 0.01560.008
CD34
+KDR
+CD133
+ cells/MNC, % Con 0.00860.003 0.01160.003 0.00760.003
ARDS 0.00760.004 0.02260.007{ 0.01660.006
G-CSF 0.00860.005 0.00960.004* 0.00460.003
iNO 0.00860.004 0.01260.005 0.00760.004
KDR
+CD133
+ cells/MNC, % Con 0.00860.003 0.01160.005 0.01160.006
ARDS 0.00760.004 0.02860.012{ 0.01460.005
G-CSF 0.00960.004 0.01160.006* 0.00560.003
iNO 0.00960.004 0.01360.007* 0.00860.003
Values are means 6 SD. MNC, mononuclear cells.
*P,0.05 vs. ARDS;
{P,0.05 vs. Con.
doi:10.1371/journal.pone.0033859.t005
Table 6. Cytokine concentrations in plasma evaluated by ELISA.
Group VEGF (ng/l) SDF-1 (ı `g/l)
Baseline
(n=6) 0 h (n=6) 24 h (n=6) 72 h (n=5–6) 168 h (n=5–6)
Baseline
(n=6) 0 h (n=6) 24 h (n=6) 72 h (n=5–6)168 h (n=5–6)
Con 264647.3 288660.9 316698.5 292627.7 2486110 4.760.9 4.460.9 3.960.8 4.461.0 4.261.2
ARDS 299633.7 294654.8 3146116 256681.1 257683.9 4.460.5 5.460.8 4.161.2 4.361.3 4.061.2
G-CSF 279629.0 316633.3 309663.3 387645.1{ 293676.5 5.161.3 3.961.3 4.161.2 4.360.8 4.461.4
iNO 308627.8 331640.1 357644.9 478663.3*
1{ 352631.9 5.161.2 5.061.2 5.160.9 6.061.2*{ 5.860.6
Values are means 6 SD.
*P,0.05 vs. ARDS;
1P,0.05 vs. Con;
{P,0.05 vs. Baseline,
{P,0.01 vs. Baseline.
doi:10.1371/journal.pone.0033859.t006
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iNO increased the WBC counts compared with ARDS (Table 3).
There was no difference in the level of EPCs (CD34
+KDR
+,
KDR
+CD133
+, and CD34
+KDR
+CD133
+ cells) among the four
groups either in peripheral blood or in bone marrow at baseline
(Table 4). In the blood, the numbers of various EPC types in the
ARDS group did not differ from those in the Con group at any
time point (Table 4). These results suggest impairment in EPC
mobilization from bone marrow into circulation in ARDS. Inhaled
NO significantly increased circulating EPC numbers (in all three
EPC typs) compared to ARDS at 24 h, and this increase was
sustained up to 168 h for CD34
+KDR
+ and KDR
+CD133
+ EPCs.
The percentage of CD34
+KDR
+/MNC was also higher in iNO
than ARDS at 24 and 72 h (Table S2). No differences were
detected in the EPC numbers between G-CSF and ARDS at 24 h.
However, we observed an elevation in the number of
CD34
+KDR
+ cells at 72 h and in the number of all types of
EPCs at 168 h in G-CSF compared to ARDS, along with
Figure 2. Effects of iNO on NO2
2/NO3
2 and MMP-9 in bone
marrow. (A) In the iNO group, the NO2
2/NO3
2 concentration was
increased at 72 h compared to the ARDS group. In the ARDS group, the
NO2
2/NO3
2 level decreased at 24 and 72 h compared to baseline. (B)
MMP-9 expression measured by Zymography in bone marrow, A–D
represent ARDS, G-CSF, iNO and Con, respectively. (C) Inhaled NO
enhanced the MMP-9 expression at day 1 and 3. (* P,0.05 vs. B; {
P,0.05 vs. ARDS group. n=5–6 in each group).
doi:10.1371/journal.pone.0033859.g002
Table 7. Lung injury score, LPI and W/D ratio in different groups.
Group Edema Neutrophil infiltration Hemorrhage Bronchiole epithelial desquamation W/D LPI
Con (n=6) 0.260.4 0.360.5 0.260.4 0.460.5 4.860.4 2.560.9
ARDS (n=5) 1.360.9 2.061.2 1.561.2 1.460.6 5.960.3 11.465.0
G-CSF (n=5) 0.460.5 2.360.9 0.360.5 0.660.4* 5.360.2 4.362.4*
iNO (n=6) 0.360.5* 1.060*{ 0.260.4 0.560.5* 5.260.3* 3.761.5*
Values are means 6 SD. W/D, wet-to-dry lung weight ratio; LPI, lung permeability index.
*P,0.05 vs. ARDS,
{P,0.05 vs. G-CSF.
doi:10.1371/journal.pone.0033859.t007
Figure 3. Vessel density of animals in different groups at day 7.
(A) Representative photomicrographs (6400) illustrating Factor VIII
staining to identify blood vessels in the lung. (B) The number of vessels
per high-powered field is significantly higher in the iNO group relative
to the ARDS group. (* P,0.05 vs. ARDS group, n=5–6 in each group).
doi:10.1371/journal.pone.0033859.g003
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+KDR
+ at 72 h and
CD34
+KDR
+ and KDR
+CD133
+ at day 7 (Table S2). The
increase of CD34
+KDR
+ cells in the G-CSF group compared to
ARDS group was more pronounced than that of the iNO group
compared to ARDS group at 168 h.
In bone marrow, the percentages of all three types of EPCs were
higher in ARDS versus Con at 24 h. Interestingly, iNO and G-
CSF reduced the percentage of KDR
+CD133
+ cells in bone
marrow at 24 h compared to the ARDS. The percentage of
CD34
+KDR
+CD133
+ EPCs was also lower in the G-CSF group
relative to ARDS group. There was a trend towards a reduction in
the percentage of bone marrow CD34
+KDR
+ cells in both iNO
and G-CSF groups compared to ARDS at 24 h (Table 5).
Effects of iNO on plasma and bone marrow EPC
mobilizing cytokines during lung injury
There was no significant difference in plasma SDF-1 and VEGF
concentrations between groups at baseline (Table 6). The plasma
VEGF and SDF-1 levels were not change significantly different
between ARDS and Con at any time point. In comparison with
the ARDS group, the iNO group showed an elevation in the
plasma VEGF (256681.1 vs. 478663.3 ng/l, p,0.05, respective-
ly) and SDF-1 (4.361.3 vs. 6.061.2 mg/l, p,0.05, respectively) at
72 h. G-CSF treatment increased the VEGF concentration but
did not affect the level of SDF-1 at any time point.
No significant difference was observed in bone marrow plasma
NO2
2/NO3
2 concentrations between groups at baseline. ARDS
animals demonstrated a marked decline in the concentrations of
NO2
2/NO3
2 at 24 and 72 h (Figure 2A). The NO2
2/NO3
2 level
in bone marrow was higher in iNO animals versus ARDS at 72 h
(Figure 2A). However, NO2
2/NO3
2 was not increased in bone
marrow in the G-CSF group.
Gelatin zymography analysis demonstrated that, compared to
ARDS, iNO augmented the expression of MMP-9 in bone
marrow at 24 and 72 h, while bone marrow MMP-9 expression
was increased in the G-CSF group at 72 h (Figure 2B and C).
Inhaled NO restores lung vascular growth and improves
lung histology via EPC mobilization
There was a trend towards improvement in ELWI and PVPI in
the iNO and G-CSF groups, whereas the ARDS group showed
deterioration, during the first 12 h. The values of ELWI and PVPI
were dramatically decreased in iNO compared to ARDS
(13.261.6 vs. 24.769.2 and 4.660.6 vs. 6.161.1, respectively)
at 24 h. The LPI was lower in iNO than in ARDS. The Lung W/
D ratio was also decreased in the iNO group compared to the
ARDS group at day 7 (Table 7).
The iNO animals exhibited higher factor VIII-positive vessel
density than the ARDS group (Figure 3A and B). G-CSF
treatment did not significantly change the vessel density compared
to the ARDS group.
Lung histology from the ARDS group was characterized by
atelectatic, congested and edematous with hemorrhagic spots
(Figure 4). As indicated by the lung injury score, there was mildly
less severe hemorrhage, but dramatically alleviated edema,
neutrophil infiltration and alveolar epithelial desquamation in
the iNO group compared to the ARDS group (Table 7). There
was also attenuated alveolar epithelial desquamation in the G-CSF
group. However, lung inflammation was more prominent in the
G-CSF than the iNO group.
TUNEL staining exhibited little or no labeling in Con animals,
while more cells with intense labeling were present in lungs of
ARDS group animals. The apoptotic index was markedly reduced
in the iNO group compared to the ARDS group (Figure 5).
CD34 mRNA level did not change greatly in the ARDS group,
as compared to Con. CD34 mRNA expression was 4-fold greater
in the iNO group than in the ARDS group. CD133 mRNA
expression was also elevated in the iNO group compared to the
Figure 4. Lung histology from animals of different groups at day 7. Lung sections were stained with hematoxylin and eosin (HE) and
inflammation cell infiltration, edema and hemorrhage were visualized at 2006 magnification. Oleic acid and mechanical ventilation resulted in
atelectatic, congested and edematous lung, with hemorrhagic spots in the lung. There was significantly alleviated edema, neutrophil infiltration and
alveolar epithelial desquamation in the iNO group compared to the ARDS group.
doi:10.1371/journal.pone.0033859.g004
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CD133 mRNA expression between G-CSF and ARDS groups.
Inhaled NO increases VEGF, VEGFR2, and eNOS
expression
There was no difference in VEGF and VEGFR2 mRNA
expression between ARDS and Con groups. Lung VEGF and
VEGFR2 mRNA expression was significantly higher in iNO
animals, but not G-CSF animals, compared to ARDS (Figure 7A).
As determined by western blot analysis, lung VEGF and VEGFR2
protein was elevated in iNO relative to ARDS (Figure 7B).
Moreover, immunochemistry of lung sections also showed stronger
VEGFR2 staining in the iNO group than in the ARDS group
(Figure 7C). Increased eNOS mRNA expression was also noted in
the iNO group, as reflected by the immunohistochemical staining
(Figure 8A and B).
Discussion
Diffuse endothelial damage is a hallmark of ARDS. Potential
therapies targeted at repair of endothelial damage have not been
thoroughly explored. It is believed that EPCs could be a prognostic
biological marker and that EPC mobilization could ameliorate
lung injury. However, little is known about the dynamics of EPC
mobilization and homing during the course of ARDS or the long
term therapeutic efficacy of EPC mobilization on lung vascular
and tissue repair.
To date, no consensus has yet been reached on the definition
of EPCs or methods for their identification. The CD34
+
KDR
+CD133
+ cells are widely accepted as circulating EPC. Flow
cytometric analyses of three surface antigens and corresponding
subpopulations of EPCs (CD34
+KDR
+, KDR
+CD133
+ and
CD34
+KDR
+CD133
+ cells) have been used for EPCs enumera-
tion, and have been shown to correlate with severity of disease
state in many studies [8,28,32]. Subsequently, some studies
indicated different phenotype of EPC, for example, Case et al
[33] reported that CD34
+CD133
+VEGFR2
+ cells do not sponta-
neously form capillary-like structures with lumens. Further studies
are required regarding the specific phenotypic of EPC to develop
the consensus definition on EPC and to understand its role in
vascular repair. Despite the controversy, the triple-positive cell
population was still used for the enumeration of EPC in recent
published articles [34,35]. Therefore, we still chose the combina-
tions of antigens to detect different EPC populations.
Previous studies have shown that bone marrow EPCs are
released into peripheral blood during ALI/ARDS [7,8], and
notably, an insufficient number of circulating EPCs has been
correlated with adverse outcomes in ARDS [8,9]. Recent evidence
suggests that intravenous EPC transplantation promotes the
integrity of lung vessels after lung injury [36–38]. However, the
clinical application of cell-therapy is limited by several factors,
such as the scarcity of circulating EPCs and the technical difficulty
Figure 5. Effects of iNO on apoptosis of lung tissue cells at day
7. (A) Representative images of lung sections showing the TUNEL
staining. (B) Bar graph showed the ratio of TUNEL-positive cells was
decreased in the iNO group compared to the ARDS group. (* P,0.05 vs.
ARDS group, n=5–6 in each group).
doi:10.1371/journal.pone.0033859.g005
Figure 6. Lung CD34 and CD133 mRNA expression at day 7. In the iNO group, lung CD34 (A) and CD133 (B) mRNA levels were increased
compared to the Con and ARDS groups. (* P,0.05 vs. ARDS group; { P,0.05 vs. Con group; n=5–6 in each group).
doi:10.1371/journal.pone.0033859.g006
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marrow may provide a less cumbersome and potentially more
effective strategy to achieve therapeutic angiogenesis. G-CSF is
one of the prototypical mobilizing cytokines that has been used for
stem cell and EPC mobilization in cardiovascular diseases. NO-
mediated EPC release into circulation and subsequent angiogen-
esis has been described previously. Inhaled NO has been
demonstrated to improve oxygenation and preserve vascular
growth of lung in a BPD model [21–23]. In the present study, we
used iNO treatment as a strategy to stimulate the mobilization of
EPCs and compared its effects with G-CSF. Our results showed
that G-CSF mobilized EPCs from the bone marrow after 3 days’
administration, which was consistent with previous reports [39],
but iNO treatment increased the number of EPCs more rapidly
than G-CSF. Higher levels of EPCs in the blood were observed on
day 7 in the G-CSF group, possibly due to the 7 day
administration of G-CSF, while NO inhalation was only
administered for 48–72 h along with mechanical ventilation.
These findings suggest that iNO has a profound effect on EPC
mobilization.
It is well established that endothelial-active cytokines, such as
VEGF and SDF-1 induce EPC mobilization [10]. Previous studies
have demonstrated that activation of VEGF/eNOS signaling
induces bone marrow NO production and subsequent up-
regulation of MMP-9 expression [40]. Of interest here, plasma
concentrations of SDF-1 and VEGF were elevated in the iNO
Figure 7. Effects of iNO on lung VEGF and VEGFR2 expression at day 7. (A) VEGF and VEGFR2 mRNA expression levels (normalized to
GAPDH) were increased in the iNO group compared to the ARDS and Con groups. (B) Representative blots for VEGF and VEGFR2 (top) and bar graph
for band densitometry (bottom). (C) Representative immunohistochemical images showed enhanced VEGFR2 expression in the iNO group compared
to the ARDS group. (* P,0.05 vs. ARDS group; { P,0.05 vs. Con group. n=5–6 in each group).
doi:10.1371/journal.pone.0033859.g007
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expression in bone marrow. These data suggest a possible
mechanism whereby iNO acts to increase the mobilization factors,
SDF-1 and VEGF, and therefore promote EPC mobilization.
However, the precise mechanism by which inhaled NO enhances
EPC mobilization and improves the lung repair remains to be
defined.
Mobilization of EPCs might result in accelerated regeneration
and a promotion in the repair process of injured vessels [41]. We
found that iNO promoted the integrity of pulmonary endothelium,
increased the vascular density and alleviated the lung histological
injury compared to ARDS. Multiple lines of evidence suggest that
EPCs are recruited to sites of injury and participate in the tissue
repair [42]. Here, we showed that iNO treatment augmented the
mRNA expression of EPC surface markers CD34 and CD133 in
lung tissue. VEGF is an important growth factor in vasculogenesis
and angiogenesis during lung development. Moreover, accumu-
lating evidence suggests that VEGF and eNOS play critical roles in
EPC mobilization, adhesion and incorporation into damaged
vessels [12,43,44]. VEGF exerts its biological effect on vascular
endothelium through specific receptors, especially VEGFR2. In
accordance with previous studies [20,23,45], we found that iNO
up-regulated VEGF and VEGFR2 expression in the lung on day
7, compared to the ARDS group. Our data also showed that iNO
enhanced the lung tissue eNOS expression. Collectively, our data
suggests that inhaled NO promotes angiogenesis and reendothe-
lization of pulmonary vascular endothelium, thereby improving
lung repair. The beneficial effects of iNO are likely due to the
promotion of mobilization and homing of EPCs.
One of the major limitations of this study is that we did not
measure the EPC number in lung tissue and therefore were unable
to evaluate the incorporation of circulating EPCs into the lung.
However, we determined the CD34 and CD133 mRNA
expression levels, which partially reflects the EPC levels in lung.
The effects of iNO on the VEGF/eNOS or SDF/CXCR4 signal
pathways of EPCs homing and recruitment have not been
demonstrated. Some studies showed that multiple pathways affect
trafficking of EPCs to sites of injury. More studies are needed to
Figure 8. Effects of iNO on lung eNOS expression at day 7. (A) eNOS mRNA expression (normalized to GAPDH) increased in the iNO group
compared to the Con group. (B) Representative immunohistochemical images show enhanced eNOS expression in iNO relative to ARDS. (* P,0.05 vs.
Con group. n=5–6 in each group).
doi:10.1371/journal.pone.0033859.g008
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lung tissue. In addition, studies have shown that the role of EPCs is
not only to repair or regenerate damaged vasculature, but also to
produce several cytokines, such as IL-10. Cytokine levels were not
examined in this study.
In conclusion, we have provided substantial evidence demon-
strating that inhaled NO mobilizes bone marrow EPCs into
circulation and attenuates damage of lung alveolar-capillary
barrier in ARDS. These findings suggest a feasible therapy for
ARDS. The mechanism of EPC mobilization, homing to injured
lungs and subsequent involvement in lung repair is a more
complicated process, requiring further investigation.
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